Abstract:The targeted delivery of anti-tumor drugs to diseased sites is significant in cancer therapy. Herein, a novel redox-responsive 5-fluorouracil (5-FU) prodrug delivery system based on mesoporous silica nanoparticles was proposed, in which polyethyleneimine (PEI, a bulky gatekeeper) and (3-aminopropyl) triethoxysilane-functionalized MCM41 were conjugated to an identical 3,3-diselanediyldipropionic acid linker via a condensation reaction between the amino group and carboxyl functional group. The chemotherapeutic reagent 5-FU was filled into the pores of Se-MCM41 nanocarriers as a model drug. The nanoparticles of PEI-Se-MCM41@5-FU exhibited a uniform and spherical morphology of approximately 175 nm. Under high concentrations of reactive oxygen species or glutathione (GSH) environments, such as the tumor microenvironment, 5-FU was rapidly released from the PEI-Se-MCM41 nanocarrier owing to its high sensitivity to both oxidizing and reducing agents. The release performance clearly verified the feasibility of PEI-Se-MCM41@5-FU nanoparticles for H 2 O 2 /GSH-triggered 5-FU release, particularly under GSH conditions. Additionally, the cytotoxic effects of PEI-Se-MCM41 nanoparticles findings indicating that there was no significant cytotoxicity against CT-26 colon cancer cells after 24 h incubation. However, PEI-Se-MCM41@5-FU nanoparticles exhibited a pronounced inhibitory effect on CT-26 cells at a concentration of 150 μg mL −1 . Furthermore, the intracellular drug delivery performance of nanocarriers were evaluated using confocal laser scanning microscopy (CLSM), which disclosed that the PEI-Se-MCM41@RhB was successfully endocytosed into the CT-26 cells and released the loaded 5-FU. The conclusion was further proved by FACS analysis, which indicated that PEI-Se-MCM41@RhB was more easily uptaken into the CT-26 cells than free RhB. The findings of in vivo and in vitro studies suggest that PEI-Se-MCM41@5-FU holds great potential for effective tumor therapy.

An Integrin-Targeting Nanosystem As a Carrier of the Selenadiazole Derivative to Induce ROS-mediated Apoptosis in Bladder Cancer Cells, from Rational Design to Action Mechanisms

Rational Design of Cancer-Targeted Benzoselenadiazole by Rgd Peptide Functionalization for Cancer Theranostics

Ultrasound-Enhanced Reactive Oxygen Species Responsive Charge-Reversal Polymeric Nanocarriers for Efficient Pancreatic Cancer Gene Delivery.

Highly Stable Selenadiazole Derivatives Induce Bladder Cancer Cell Apoptosis and Inhibit Cell Migration and Invasion Through the Activation of ROS-mediated Signaling Pathways

Rational Design of Cancer-Targeted Selenadiazole Derivative As Efficient Radiosensitizer for Precise Cancer Therapy

Rational design and fabrication of a cancer-targeted chitosan nanocarrier to enhance selective cellular uptake and anticancer efficacy of selenocystine

Tailored Mesoporous Silica Nanosystem with Enhanced Permeability of the Blood-Brain Barrier to Antagonize Glioblastoma

Enzymatic interlocking aptamer-micelles for enhanced cellular internalization and nucleus-targeted cancer phototherapy

An esterase-activatable prodrug formulated liposome strategy: potentiating the anticancer therapeutic efficacy and drug safety

Engineering Thio-/seleno-ether Linkers into Zwitterionic Small Molecule Nano-prodrugs for Traceable Cancer Theranostics

Enzyme-Induced and Tumor-Targeted Drug Delivery System Based on Multifunctional Mesoporous Silica Nanoparticles

Dual-function Nanosystem for Synergetic Cancer Chemo-/Radiotherapy Through ROS-mediated Signaling Pathways.

ROS-sensitive PD-L1 siRNA cationic selenide nanogels for self-inhibition of autophagy and prevention of immune escape

Selective Cellular Uptake and Induction of Apoptosis of Cancer-Targeted Selenium Nanoparticles.

Rational Design of Cancer-Targeted BSA Protein Nanoparticles As Radiosensitizer to Overcome Cancer Radioresistance

Targeted Delivery of Catalase and Photosensitizer Ce6 by a Tumor-Specific Aptamer is Effective Against Bladder Cancer in Vivo.

Carboxylated mesoporous silica nanoparticle-nucleic acid chimera conjugate-assisted delivery of siRNA and doxorubicin effectively treat drug-resistant bladder cancer.

ROS/GSH dual-responsive selenium-containing mesoporous silica nanoparticles for drug delivery

Selenomethionine-Conjugated Extracellular Vesicles for ROS-Mediated Cell Apoptosis

Self-crosslinkable chitosan-hyaluronic acid dialdehyde nanoparticles for CD44-targeted siRNA delivery to treat bladder cancer

Designing Bioresponsive Metal Azolate Framework-Based Nanosystem for Efficient Cancer Therapy